Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Malignant Disease × Docetaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 52 Neoplasms 44 Prostatic Neoplasms 43 Breast Neoplasms 38 Neoplasm Metastasis 21 Unspecified Adult Solid Tumor, Protocol Specific 19 Lung Neoplasms 18 Head and Neck Neoplasms 17 Squamous Cell Carcinoma of Head and Neck 16 Ovarian Neoplasms 15 Advanced Solid Tumors 11 Stomach Neoplasms 9 Sarcoma 9 Pancreatic Neoplasms 9 Solid Tumor 8 Melanoma 8 Esophageal Neoplasms 8 Carcinoma, Ovarian Epithelial 8 Urinary Bladder Neoplasms 7 Fallopian Tube Neoplasms 7 Colorectal Neoplasms 7 Small Cell Lung Carcinoma 6 Salivary Gland Neoplasms 6 Esthesioneuroblastoma, Olfactory 5 Esophageal Squamous Cell Carcinoma 5 Carcinoma, Renal Cell 5 Breast Neoplasms, Male 5 Triple Negative Breast Neoplasms 4 Recurrence 4 Endometrial Neoplasms 4

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡